These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 7628176)
1. Success rates for new drugs entering clinical testing in the United States. DiMasi JA Clin Pharmacol Ther; 1995 Jul; 58(1):1-14. PubMed ID: 7628176 [No Abstract] [Full Text] [Related]
2. Recombinant protein therapeutics--success rates, market trends and values to 2010. Pavlou AK; Reichert JM Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654 [No Abstract] [Full Text] [Related]
4. Key factors in the rising cost of new drug discovery and development. Dickson M; Gagnon JP Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789 [No Abstract] [Full Text] [Related]
5. Monoclonal antibody successes in the clinic. Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394 [TBL] [Abstract][Full Text] [Related]
6. The right to a trial: Should dying patients have access to experimental drugs? Groopman J New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539 [No Abstract] [Full Text] [Related]
7. Pharmacogenomics. Going from genome to pill. Service RF Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283 [No Abstract] [Full Text] [Related]
8. Trading on traditional medicines. Basu P Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941 [No Abstract] [Full Text] [Related]
9. The origins of new drugs. Kneller R Nat Biotechnol; 2005 May; 23(5):529-30. PubMed ID: 15877061 [No Abstract] [Full Text] [Related]
10. Good clinical practice in clinical drug trials--what you need to know. Soyebi K; Abosede ; Coker HA; Osuntoki ; Oyibos W; Keri H; Ogunsola S Nig Q J Hosp Med; 2008; 18(2):104-12. PubMed ID: 19068563 [No Abstract] [Full Text] [Related]
11. In vivo pharmacology in drug discovery and development. Svendsen O; Ahnfelt-Rønne I; Vanhoutte P Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):89-90. PubMed ID: 16918707 [No Abstract] [Full Text] [Related]
12. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related]
13. Risks, regulation, and rewards in new drug development in the United States. DiMasi JA Regul Toxicol Pharmacol; 1994 Apr; 19(2):228-35. PubMed ID: 8041920 [No Abstract] [Full Text] [Related]
14. US court rules to allow experimental drugs for dying patients. Waltz E Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988 [No Abstract] [Full Text] [Related]
15. Metabolites in safety testing: "MIST" for the clinical pharmacologist. Frederick CB; Obach RS Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437 [No Abstract] [Full Text] [Related]
16. Surviving the blockbuster syndrome. Service RF Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490 [No Abstract] [Full Text] [Related]
18. Paediatric clinical trials: redressing the imbalance. Schreiner MS Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794 [No Abstract] [Full Text] [Related]
19. Pharma's year of trouble and strife. Frantz S Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339 [No Abstract] [Full Text] [Related]
20. Institute of Medicine's new drug safety report: implications for Canada. Cassels A CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086 [No Abstract] [Full Text] [Related] [Next] [New Search]